Artgen Biotech PJSC (MIC:ABIO) Current Accrued Expense : ₽0 Mil (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Current Accrued Expense?

Artgen Biotech PJSC's Current Accrued Expense for the quarter that ended in Jun. 2023 was ₽0 Mil.

Artgen Biotech PJSC Current Accrued Expense Historical Data

The historical data trend for Artgen Biotech PJSC's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Current Accrued Expense Chart

Artgen Biotech PJSC Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Current Accrued Expense

Get a 7-Day Free Trial

Artgen Biotech PJSC Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Artgen Biotech PJSC Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Artgen Biotech PJSC Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prospect of the 60th Anniversary, Moscow, RUS, 117036

Website

https://www.hsci.ru

Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.